AeroLeads people directory · profile

Kathy Harrison Gaicd Email & Phone Number

Biotechnology Company Director at HAVAH Therapeutics
Location: Australia, Australia, Australia 15 work roles 6 schools
1 work email found @protatherapeutics.com LinkedIn matched
✓ Verified Jun 2026 4 data sources Profile completeness 100%

Contact Signals · 1 work email

Work email k****@protatherapeutics.com
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
Biotechnology Company Director
Location
Australia, Australia, Australia

Who is Kathy Harrison Gaicd? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Kathy Harrison Gaicd is listed as Biotechnology Company Director at HAVAH Therapeutics, based in Australia, Australia, Australia. AeroLeads shows a work email signal at protatherapeutics.com and a matched LinkedIn profile for Kathy Harrison Gaicd.

Kathy Harrison Gaicd previously worked as Board Member - USA at Havah Therapeutics and CEO (Australia) at Havah Therapeutics. Kathy Harrison Gaicd holds Graduate from Australian Institute Of Company Directors.

Company email context

Email format at HAVAH Therapeutics

This section adds company-level context without repeating Kathy Harrison Gaicd's masked contact details.

*@protatherapeutics.com
68% confidence

AeroLeads found 1 current-domain work email signal for Kathy Harrison Gaicd. Compare company email patterns before reaching out.

Profile bio

About Kathy Harrison Gaicd

Australian biotechnology Company Director and CEO with more than 30 years of experience including in 4 ASX listed biotechnology companies and 9 years of patent attorney practice. Scientist and Patent Attorney by training, Kathy has successfully created value by transitioning biotechnology companies through critical drug development stages. Kathy lead Dimerix Ltd from a private pre-clincial company to an ASX listed company with Phase 2 proof of concept data. Dimerix is now completing a global phase 3 clincial trial. Kathy has subsequently positioned Havah Therapeutics Pty Ltd to access a US based phase 2 trial with the leading breast cancer platform trial consortium (I-SPY), and transitioned the company into a US head quartered entity, positioning it for global growth through access to the deep capital and partnership networks in the USA.Kathy was also selected to participate in the inaugural 2018 SBE Australia Life Sciences Accelerator Program, and is now part of the prestigious US Springboard Alumni Network. Specialties: Accelerating clinical treatment opportunities through critical milestones. Identifying and executing on niche intellectual property opportunities. Building and leading teams. Identification of efficient approaches to drug development opportunities and delivering on project outcomes.

Listed skills include Biotechnology, Intellectual Property, Patents, Technology Transfer, and 15 others.

Current workplace

Kathy Harrison Gaicd's current company

Company context helps verify the profile and gives searchers a useful next step.

HAVAH Therapeutics
Havah Therapeutics
Biotechnology Company Director
AeroLeads page
15 roles

Kathy Harrison Gaicd work experience

A career timeline built from the work history available for this profile.

Board Member - Usa

Current

North Adelaide, South Australia, AU

Jun 2024 - Present

Ceo (Australia)

North Adelaide, South Australia, AU

HAVAH Therapeutics is a women’s health specialty biopharmaceutical company, focused on developing innovative, proprietary hormonal therapies that aim to help millions of women across the world lead longer, better lives. In 2023, the Havah Therapeutics active agent was included in the most recent clinical trial initiated by the prestigious I-SPY breast.

Nov 2019 - Jun 2024

Managing Director

Current

Estrenue is developing a treatment for skin integrity (anti-aging) that delivers generic estradiol to the dermal layers of the skin utilizing a novel non-invasive micro-technology delivery system: Elongated Microparticles (EMP). As Managing Director, Kathy has led the company through 2 seed rounds raising approximately AUD1.4M and overseen development of.

Nov 2021 - Present

Life Science Executive Committee Member

Current

Sydney, NSW, AU

Dec 2018 - Present

Alumnae

Current

Sydney, NSW, AU

I accelerated my business by completing the 2018 BIOTECH program

Apr 2018 - Present

Head Of Ip Strategy

Prota Therapeutics Pty Ltd

Prota Therapeutics is an Australian private company developing immunotherapy based treatments for food allergy. The company’s lead product, based on technology spun out of the Murdoch Children's Research Institute, is under development as a treatment for the most common cause of life-threatening anaphylaxis, peanut allergy.Kathy’s role is to optimise the.

Feb 2019 - Jan 2022

Director

Disruptive Nutrition Pty Ltd

Disruptive Nutrition was a subsidiary of Disruptive Enterprises LLC, focused on advancing disease research and developing formulations as medical foods to potentially benefit patients. Disruptive Nutrition has conducted clinical a safety/tolerability clinical trial in children with Angelman Syndrome at the Vanderbilt Children's hospital.Disruptive.

May 2019 - Dec 2020

Chief Operating Officer

Melbourne, Victoria, AU

Dimerix Limited is an ASX listed Australian Clinical Stage Biotechnology company. Dimerix's lead therapy (DMX-200) is a new therapeutic approach to treating chronic kidney disease. During this period Kathy ensured a seamless transition to the new CEO

Aug 2018 - Nov 2018

Chief Executive Officer

Melbourne, Victoria, AU

As CEO, Kathy raised $9.5m on the ASX in 13 months on a company capitalised at the time of $10m, and built her team from 1 part time employee to a team of 6 including a Chief Medical Officer and Head of Drug Development.Kathy also delivered positive Phase 2a data in the chronic kidney disease trial, developed an extended release tablet formulation and.

Nov 2016 - Aug 2018

General Manager

Melbourne, Victoria, AU

Commenced as sole full time employee reporting directly to the Board of Directors to take lead clinical pre-clinical asset, DMX-200 into Phase 2 clinical trials, and list company on the ASX. Recruited 27 patients into Phase 2a study, ultimately generating positive safety and indications of efficacy data.Accelerated patent prosecution leading to grant of.

Mar 2014 - Nov 2016

Vice President, Ip & Product Development

Clayton, Victoria, AU

Strategic creation of intellectual property solutions for a range of commercialisation scenarios. Analysis and preparation of business case for commercial opportunities. Project leader for successful phase II clinical trial for an acne treatment. Implementation of product distribution projects. R&D tax incentive applications and overseas advanced findings..

Nov 2009 - Feb 2014

Hr Manager

Clayton, Victoria, AU

Consolidation and implementation of HR systems and processes including creation and implementation of annual performance review process and staff HR manual.

Dec 2010 - Sep 2012

Head, Intellectual Property

Ym Biosciences Australia (Formerly Cytopia Research Pty Ltd)

As secretary of the due diligence committee, pivotal role in the merger of Cytopia into YM Biosciences, which was ultimately sole to Gilead based on the lead clinical asset (momelitinib or CYT387) acquired from Cytopia.Earlier roles at Cytopia included Drafting and prosecution of new patent applications and strategic patent advice; patent portfolio.

Dec 2006 - May 2010

Associate Patent Attorney

Hawthorn, Victoria, AU

Patent practice for chemical, biotechnology and pharmaceutical clients. Australian patent and trade mark oppositions. Trade mark searching and advice for a range of clients including in the food, fashion, consumer chemical and electronic device industries. Plant Breeders Rights.

Sep 1997 - Dec 2006

Technology Transfer Coordinator

Amrad

Sourcing and evaluating new potential diagnostic and research reagent products.

Dec 1992 - Sep 1997
6 education records

Kathy Harrison Gaicd education

Graduate

Australian Institute Of Company Directors

Certificate In Governance Practice

Governance Institute Of Australia

Diploma In Intellectual Property Practice

The Institute Of Patent And Trade Mark Attorneys Of Australia (Ipta)

Grad Dip Ip Law, Ip Law

University Of Melbourne

Msc, Molecular Biology

The University Of Manchester

Bappsc, Chemistry, Biochemistry

Swinburne University Of Technology
FAQ

Frequently asked questions about Kathy Harrison Gaicd

Quick answers generated from the profile data available on this page.

What company does Kathy Harrison Gaicd work for?

Kathy Harrison Gaicd works for HAVAH Therapeutics.

What is Kathy Harrison Gaicd's role at HAVAH Therapeutics?

Kathy Harrison Gaicd is listed as Biotechnology Company Director at HAVAH Therapeutics.

What is Kathy Harrison Gaicd's email address?

AeroLeads has found 1 work email signal at @protatherapeutics.com for Kathy Harrison Gaicd at HAVAH Therapeutics.

Where is Kathy Harrison Gaicd based?

Kathy Harrison Gaicd is based in Australia, Australia, Australia while working with HAVAH Therapeutics.

What companies has Kathy Harrison Gaicd worked for?

Kathy Harrison Gaicd has worked for Havah Therapeutics, Estrenue Pty Ltd, Sbe Australia, Prota Therapeutics Pty Ltd, and Disruptive Nutrition Pty Ltd.

How can I contact Kathy Harrison Gaicd?

You can use AeroLeads to view verified contact signals for Kathy Harrison Gaicd at HAVAH Therapeutics, including work email, phone, and LinkedIn data when available.

What schools did Kathy Harrison Gaicd attend?

Kathy Harrison Gaicd holds Graduate from Australian Institute Of Company Directors.

What skills is Kathy Harrison Gaicd known for?

Kathy Harrison Gaicd is listed with skills including Biotechnology, Intellectual Property, Patents, Technology Transfer, Commercialization, Strategy, Product Development, and Patent Prosecution.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.